Yazar "Schierz, Jan-Henning" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Assessing the Correlation Between 68Ga-PSMA-11 Renal PET Parameters and Renal Function Tests
    (Soc Nuclear Medicine Inc, 2022) Schierz, Jan-Henning; Sarikaya, Ismet; Albatineh, Ahmed N.; Sarikaya, Ali
    Ga-68-prostate-specific membrane antigen (PSMA) ligands are used for prostate cancer but also show high renal cortical uptake. In this study, we aimed to assess whether there is any correlation between renal PSMA PET parameters and renal function tests using the images of prostate cancer patients. Methods: (68)GaPSMA-11 PET/CT images of the patients with prostate cancer were retrospectively evaluated. The following PET parameters were obtained: SUVmax, SUVmean, SUVmax corrected for lean body weight, SUVmean corrected for lean body weight, volume, lean body weight-corrected total lesion glycolysis (TLG(SUL)), and counts of both kidneys, as well as SUVmean of the liver, blood pool, and spleen. Total TLG(SUL), total volume, kidney-to-liver ratio, and kidney-to-blood pool ratio were calculated. Creatinine values were obtained, and glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease formula. Statistical analysis was performed to understand whether there is a correlation between the above parameters and renal function tests. Results: Twenty-five patients were included in this study. GFR was significantly and positively correlated and creatinine was significantly and negatively correlated with the ratios of renal SUV to liver SUV and renal SUV to blood pool SUV. GFR was marginally positively correlated with renal SUVmean corrected for lean body weight, and creatinine was marginally negatively correlated with total TLG(SUL). Total renal parenchymal volume was significantly and directly (positively) associated with GFR and significantly and inversely (negatively) associated with creatinine. Conclusion: Renal Ga-68-PSMA uptake appears to be correlated with renal function tests. Our method of measuring approximate renal parenchymal volume on PET images appears to be reliable.
  • Küçük Resim Yok
    Öğe
    Immune Checkpoint Inhibitor-Related Adverse Effects and 18F-FDG PET/CT Findings
    (Soc Nuclear Medicine Inc, 2021) Schierz, Jan-Henning; Sarikaya, Ismet; Wollina, Uwe; Unger, Leonore; Sarikaya, Ali
    Immune checkpoint inhibitor (ICI) treatments activate T cells against tumors. Activated T cells attack not only the tumor but also healthy cells, causing an autoimmune reaction in various tissues. These immune-related adverse effects (IRAEs) cause F-18-FDG uptake in various tissues due to inflammation. It is important to recognize and report these findings on F-18-FDG PET/CT studies. F-18-FDG PET helps to determine the presence, location, and severity of IRAEs. In severe cases, ICI treatments are interrupted or suspended and antiinflammatory treatments are started. F-18-FDG uptake due to IRAEs may mimic metastases or disease progression. Their presence may also help in predicting response to treatment and have prognostic implications. In this review article, we provide basic information about ICI treatments, IRAEs, and F-18-FDG PET/CT findings.
  • Küçük Resim Yok
    Öğe
    Liver: glucose metabolism and 18F-fluorodeoxyglucose PET findings in normal parenchyma and diseases
    (E-Century Publishing Corp, 2021) Sarikaya, Ismet; Schierz, Jan-Henning; Sarikaya, Ali
    Liver has a complex and unique energy metabolism and plays a major role in glucose homeostasis. Liver is the main control center for glycogenesis, glycogenolysis, glycolysis and gluconeogenesis which are essential to provide energy for other tissues. Liver meets its own energy need from various sources which is mainly glucose in the fed state and fatty acids in the fasting state. In this review article, we will mainly describe the glucose metabolism of the liver, effect of various factors on 18F-fluorodeoxyglucose (FDG) activity/uptake in the normal liver and 18F-FDG positron emission tomography (PET) uptake patterns in various malignant and benign liver pathologies. Brief information on metabolomics profiling analyses in liver disorders will also be be provided.